Ignite Creation Date:
2024-05-06 @ 8:18 PM
Last Modification Date:
2024-10-26 @ 3:24 PM
Study NCT ID:
NCT06326736
Status:
RECRUITING
Last Update Posted:
2024-03-22
First Post:
2024-03-11
Brief Title:
Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer
Sponsor:
Jinling Hospital China
Organization:
Jinling Hospital China
Study Overview
Official Title:
An Exploratory Clinical Study of Safety and Efficacy of Neoantigen mRNA Vaccines in the Treatment of Patients With Resectable Pancreatic Cancer
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of treating pancreatic cancer with surgery to remove cancerour tissue followed by camrelizumab and a personalized cancer mRNA vaccines
Detailed Description:
The first purpose of this study is to evaluate the safety of treating pancreatic cancer with surgery to remove cancerour tissue
Following with camrelizumab and a personalized Neoantigen mRNA Vaccines and then with chemotherapy
Following with camrelizumab and a personalized Neoantigen mRNA Vaccines and then with chemotherapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None